Novavax Profile picture
Feb 10 22 tweets 8 min read
Today we're thrilled to announce results of our PREVENT-19 Phase 3 pediatric expansion to adolescents (ages 12 through 17). Let's talk about the data and what they mean. Thread:
Today's results build on findings from the adult main study, investigating the safety & efficacy of NVX-CoV2373 in the United States and Mexico amidst an evolving #COVID19 pandemic: nejm.org/doi/full/10.10… #clinicaltrials
The pediatric expansion randomized adolescents age 12 through 17, in the U.S., in a 2:1 ratio to receive 2x 5μg doses of NVX-CoV2373, our investigational #vaccine candidate, or placebo, 21 days apart. Protocol: novavax.com/sites/default/…
The adolescent study also included a blinded crossover, where placebo recipients received active vaccine & vice versa, ensuring all participants received NVX-CoV2373 without compromising @FDA-required safety follow-up.
We'll be talking about the study's 2 key endpoints: 1) Primary Effectiveness Endpoint: the non-inferiority of neutralizing antibody responses vs young adults (18-26) from the adult part of the study;
and 2) Primary Efficacy Endpoint: PCR-confirmed, symptomatic mild, moderate or severe #COVID19 diagnosed ≥7 days after the 2nd vaccine dose.
The trial was conducted during a time when the Delta (B.1.617.2) variant was dominant in the U.S.
Demographics of the 2,247 participants were well balanced between vaccine and placebo groups. There were more younger participants as EUA vaccines weren't available for that age group at the time.
Safety events were balanced between vaccine and placebo groups. Serious Adverse events were infrequent and balanced. No safety signals were observed.
The vaccine was well tolerated. Local reactogenicity was similar to adults. Pain & tenderness were the most common. Findings were consistent between younger and older adolescents.
Similar findings were observed for systemic reactogenicity. As with local reactogenicity, there was an increase after the second dose, as expected.
The vaccine demonstrated its effectiveness in this study: Neutralizing antibody responses were non-inferior to young adults, showing the vaccine performs in adolescents. Licensure-enabling effectivness endpoint met ✅.
Not only were neutralizing responses non-inferior, they were higher: ~1.5X higher immune responses than in adults in the Phase 3 US/MX trial, which were associated with high levels of efficacy. Seroconversion was ~99%. nejm.org/doi/full/10.10…
Overall, adolescent antibody titers were higher than in adults. Titers were higher in younger than in older adolescents.
Antibodies showed the ability to identify variants. After 2 doses, 100% had detectable IgG responses against all variants tested, including #Omicron. These responses were 2-3X higher than in adults.
Those antibodies were functional: they were able to block the binding between the virus and the human ACE2 receptor, for all variants tested. This assay shows the potential to interrupt SARS-CoV-2 mechanism of infection.
We looked at clinical efficacy against mild, moderate & severe COVID-19, 7 days after 2nd dose. 20 cases were seen: 6 in the vaccine group, 14 in placebo – for a vaccine efficacy of 79.5%. Primary efficacy endpoint met ✅.
Vaccine efficacy was very similar between older and younger children.
We saw 82% efficacy against Delta VOC, generally matching the overall efficacy observed in the adult study, where we saw efficacy >90%, including against variants, and complete protection against moderate & severe disease.
Summary: No safety signal was observed. Vaccine was well tolerated. Primary effectiveness and efficacy endpoints were met. Overall efficacy was 79.5% and 82% against Delta VOC. Findings consistent between age groups.
Novavax looks forward to supplementing our global regulatory findings with results from this pediatric expansion. Additional pediatric studies are expected to start in Q2.
Thank you. Novavax is grateful to the thousands of people around the world who are volunteering for our vaccine studies. We thank the U.S. Government, @CEPIvaccines & other governments for their significant support of our work.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Novavax

Novavax Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Novavax

Oct 11, 2021
We're thrilled to announce that PREVENT-19 (US/Mex Phase 3) results were submitted for publication. The manuscript is now available as a pre-print. Let's dive into what we found. Thread: medrxiv.org/content/10.110…
PREVENT-19 builds on observations from other/ongoing #clinicaltrials, investigating the safety & efficacy of NVX-CoV2373 in the United States and Mexico amidst an evolving #COVID19 pandemic. ir.novavax.com/2021-08-05-Nov…
The trial randomized adults age 18+ in a 2:1 ratio to receive 2x 5μg doses of NVX-CoV2373, our investigational #vaccine candidate, or placebo, 21 days apart. novavax.com/sites/default/… Image
Read 16 tweets
Sep 24, 2021
We’re proud to announce the publication of our successful Phase 3 trial of NanoFlu™, our seasonal quadrivalent Nanoparticle #Influenza #Vaccine (#qNIV) candidate, in @TheLancetInfDis. Let’s dig into why it matters: thelancet.com/journals/lanin…

Thread:
According to @CDC, “on average, about 8% of the U.S. population gets sick from #flu each season.” There is an urgent need for improved flu #vaccines, particularly for older adults (>age 65), who bear higher disease burden. cdc.gov/flu/about/keyf…
Coverage of existing flu vaccines is >60% in the US, but recent flu seasons have shown vaccine effectiveness may be just 10-13% for one virus strain (A/H3N2) in older adults. ncbi.nlm.nih.gov/pmc/articles/P…
Read 25 tweets
Aug 5, 2021
NEWS: Novavax Announces #COVID19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination ir.novavax.com/2021-08-05-Nov…
Following the primary vaccination series (21 days apart), a single booster dose at 6 months of NVX-CoV2373 induced a robust increase in anti-Spike antibody levels - up ~4.6-fold vs the response seen after the primary series.
The increased antibody response was consistent for both younger and older adults.
Read 12 tweets
Aug 5, 2021
NEWS: Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax’ Recombinant Nanoparticle #COVID19 Vaccine ir.novavax.com/2021-08-05-Nov…
The submissions were made to the Drugs Controller General of India (DCGI) and regulatory agencies in Indonesia and the Philippines.
“Today’s submission of our recombinant nanoparticle COVID-19 vaccine, the first protein-based option filed with any regulatory agency, represents a major milestone in Novavax’ transformation into a commercial global vaccine company,” said Stanley C. Erck, President and CEO
Read 5 tweets
Jan 28, 2021
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial bit.ly/2MyjKwC
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants.
Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(